Apricoxib: Difference between revisions
Content deleted Content added
m Bot: Deprecating Template:Cite doi and some minor fixes |
m Remove redundant parameters InChI, InChIKey (StdInChI, StdInChIKey are used). See Talk (via AWB script) |
||
| Line 21: | Line 21: | ||
| molecular_weight = 356.4387 g/mol |
| molecular_weight = 356.4387 g/mol |
||
| smiles = CCOC1=CC=C(C=C1)C2=CC(=CN2C3=CC=C(C=C3)S(=O)(=O)N)C |
| smiles = CCOC1=CC=C(C=C1)C2=CC(=CN2C3=CC=C(C=C3)S(=O)(=O)N)C |
||
| |
| StdInChI = 1S/C19H20N2O3S/c1-3-24-17-8-4-15(5-9-17)19-12-14(2)13-21(19)16-6-10-18(11-7-16)25(20,22)23/h4-13H,3H2,1-2H3,(H2,20,22,23) |
||
| |
| StdInChIKey = JTMITOKKUMVWRT-UHFFFAOYSA-N |
||
| StdInChI = |
|||
| StdInChIKey = |
|||
}} |
}} |
||
Revision as of 20:49, 5 April 2016
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C19H20N2O3S |
| Molar mass | 356.4387 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Apricoxib is an experimental anticancer drug in Phase II clinical trials. It is a COX-2 inhibitor which improves standard therapy response in molecularly defined models of pancreatic cancer.[1]
See also
References
- ^ Kirane, A. (2012). "Apricoxib, a Novel Inhibitor of COX-2, Markedly Improves Standard Therapy Response in Molecularly Defined Models of Pancreatic Cancer". Clinical Cancer Research. 18 (18): 5031–5042. doi:10.1158/1078-0432.CCR-12-0453.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |